Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25911876 | 0.89 | DGAT1 (0.37) | DGAT1KLKB1CYP1A2PDE10AGABRA2 | |
| SCHEMBL2822544 | 0.84 | DGAT1 (0.39) | DGAT1KLKB1CYP1A2GABRA2GABRB2 | |
| SCHEMBL1856217 | 0.82 | DGAT1 (0.44) | DGAT1KLKB1CYP1A2GABRA2GABRB2 | |
| SCHEMBL30684567 | 0.82 | DGAT1 (0.39) | DGAT1KLKB1CYP1A2GABRA2GABRB2 | |
| SCHEMBL1858664 | 0.82 | DGAT1 (0.42) | DGAT1KLKB1CYP1A2GABRA2GABRB2 | |
| SCHEMBL13733884 | 0.81 | DGAT1 (0.43) | DGAT1KLKB1CYP1A2GABRA2GABRB2 | |
| SCHEMBL18839145 | 0.80 | DGAT1 (0.37) | DGAT1KLKB1CYP1A2GABRA2GABRB2 | |
| SCHEMBL1857062 | 0.79 | DGAT1 (0.38) | DGAT1KLKB1GABRA2GABRB2GAA | |
| SCHEMBL12381794 | 0.79 | DGAT1 (0.37) | DGAT1KLKB1CYP1A2GABRA2GABRB2 | |
| SCHEMBL30824981 | 0.76 | DGAT1 (0.45) | DGAT1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099478-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-27 | — | — | US | disclosed |
| CN-118613483-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| WO-2023146809-A9 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099478-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | DGAT1 1479/4885KLKB1 1/4885CYP1A2 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.